Annovis Bio Inc. (NYSE: ANVS) to Present Recent Achievements and 2025 Strategic Outlook During Upcoming Live Investor Webcast
The webcast led by Annovis’ Founder, President and CEO, Maria Maccecchini, Ph.D., will take place on Dec. 11, at 4:30 p.m. EST. Dr. Maccecchini will provide a comprehensive view of the company’s recent achievements along with strategic initiatives for 2025, followed by a Q&A session. The company recently received FDA clearance to proceed with a pivotal Phase 3 Alzheimer’s disease program for lead drug candidate buntanetap, set to begin in early 2025. Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), will hold a…